Last reviewed · How we verify

(PN-152,243)/ PN-196,444

Pfizer · Phase 3 active Small molecule

(PN-152,243)/ PN-196,444 is a Phosphodiesterase 4 (PDE4) inhibitor Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD), Asthma.

PN-152,243/PN-196,444 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.

PN-152,243/PN-196,444 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Chronic obstructive pulmonary disease (COPD), Asthma.

At a glance

Generic name(PN-152,243)/ PN-196,444
SponsorPfizer
Drug classPhosphodiesterase 4 (PDE4) inhibitor
TargetPDE4
ModalitySmall molecule
Therapeutic areaImmunology / Respiratory
PhasePhase 3

Mechanism of action

PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce inflammation in conditions driven by excessive immune activation, particularly in respiratory and inflammatory diseases.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about (PN-152,243)/ PN-196,444

What is (PN-152,243)/ PN-196,444?

(PN-152,243)/ PN-196,444 is a Phosphodiesterase 4 (PDE4) inhibitor drug developed by Pfizer, indicated for Chronic obstructive pulmonary disease (COPD), Asthma.

How does (PN-152,243)/ PN-196,444 work?

PN-152,243/PN-196,444 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.

What is (PN-152,243)/ PN-196,444 used for?

(PN-152,243)/ PN-196,444 is indicated for Chronic obstructive pulmonary disease (COPD), Asthma.

Who makes (PN-152,243)/ PN-196,444?

(PN-152,243)/ PN-196,444 is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What drug class is (PN-152,243)/ PN-196,444 in?

(PN-152,243)/ PN-196,444 belongs to the Phosphodiesterase 4 (PDE4) inhibitor class. See all Phosphodiesterase 4 (PDE4) inhibitor drugs at /class/phosphodiesterase-4-pde4-inhibitor.

What development phase is (PN-152,243)/ PN-196,444 in?

(PN-152,243)/ PN-196,444 is in Phase 3.

What are the side effects of (PN-152,243)/ PN-196,444?

Common side effects of (PN-152,243)/ PN-196,444 include Nausea, Diarrhea, Headache, Vomiting.

What does (PN-152,243)/ PN-196,444 target?

(PN-152,243)/ PN-196,444 targets PDE4 and is a Phosphodiesterase 4 (PDE4) inhibitor.

Related